Clinical Trials | March 03, 2026
Merck’s KEYTRUDA & WELIREG combo shows breakthrough results in kidney cancer trial
Merck emphasized the broader significance of the findings
Merck emphasized the broader significance of the findings
This study evaluated a difficult-to-treat Crohn's disease patient population
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The LIFT-PD study will enroll 75 Parkinson’s patients experiencing apathy across 16 sites in Germany, Bulgaria, Poland and Spain
AA, a chronic immune disease, can cause extensive and unpredictable hair loss
Zongertinib is setting a new standard as the first targeted therapy for treatment naïve patients with HER2-mutant advanced non-small cell lung cancer with demonstrated efficacy
PEACE-3 is a strong example of how academic cooperative research can help advance progress for complex diseases such as metastatic prostate cancer
The oral therapy is aimed at adults with chronic spontaneous urticaria (CSU) who do not respond adequately to H1-antihistamines
The partnership will focus on the ongoing SYNERGY-101 randomized Phase 2 trial for first-line
BRAFTOVI in combination with cetuximab and mFOLFOX6 had previously received accelerated approval in December 2024 based on objective response rate (ORR) results
Subscribe To Our Newsletter & Stay Updated
